Icu Medical Intrinsic Stock Value – CL King Starts Coverage of ICU Medical for Investors
December 20, 2023
🌥️Trending News
CL King has recently initiated coverage of ICU ($NASDAQ:ICUI) Medical, a leading independent provider of medical products and services, for investors. ICU Medical is a publicly traded company on the Nasdaq that provides innovative medical devices used in vascular access, oncology, and critical care applications. The company’s product portfolio focuses on reducing the risk of healthcare-associated infections through the use of its specialized medical products. These include catheters, needles and syringes, IV tubing sets, safety products and custom pharmaceuticals.
ICU Medical also provides a range of services to customers, such as clinical education, reimbursement support, and validation services. With its extensive experience in the medical industry and its impressive portfolio of products and services, ICU Medical is well-positioned to benefit from the growing demand for healthcare products and services worldwide.
Market Price
Shares of ICU MEDICAL opened at $99.1 and closed at $98.1, representing a 1.3% decrease from the previous closing price of 99.4. This drop in stock price was indicative of investor uncertainty in their assessment of the company’s trajectory heading into the future. Despite this, ICU remains an attractive opportunity, offering strong potential for growth and potential return on investment. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Icu Medical. More…
| Total Revenues | Net Income | Net Margin |
| 2.25k | -28.04 | -0.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Icu Medical. More…
| Operations | Investing | Financing |
| 73.22 | -81.3 | -38.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Icu Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 4.38k | 2.28k | 86.92 |
Key Ratios Snapshot
Some of the financial key ratios for Icu Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.1% | -21.9% | 1.5% |
| FCF Margin | ROE | ROA |
| -0.6% | 1.0% | 0.5% |
Analysis – Icu Medical Intrinsic Stock Value
At GoodWhale, we have conducted an analysis of ICU MEDICAL‘s financials to determine the intrinsic value of its stock. Through our proprietary Valuation Line, we have determined that the intrinsic value of ICU MEDICAL share is roughly $233.2. However, the current stock price of ICU MEDICAL is trading at $98.1, meaning it is undervalued by 57.9%. This presents a great opportunity for investors to take advantage of the stock’s significant undervaluation. More…
Peers
It operates in a highly competitive market that includes major competitors such as Ypsomed Holding AG, Coloplast A/S, and Cardiovascular Systems Inc. These companies all strive to provide the best quality products and services to meet the needs of their customers.
– Ypsomed Holding AG ($LTS:0QLQ)
Ypsomed Holding AG is a leading Swiss medical technology company that designs, develops, and manufactures healthcare products for delivery of drugs and other treatments. The company has a market capitalization of 2.34 billion as of 2022, reflecting the confidence of investors in the company’s potential and its ability to grow in the coming years. Ypsomed Holding AG also has a Return on Equity of 4.93%, which is a measure of the company’s profitability relative to its shareholders’ equity. This indicates that the company is using its resources efficiently and delivering value to its shareholders.
– Coloplast A/S ($LTS:0QBO)
Coloplast A/S is a Danish medical device company that develops, manufactures, and markets medical products and services worldwide. The company has a market cap of 183.14B as of 2022 and a Return on Equity (ROE) of 50.58%. The market cap is an indication of the overall size of the company and its potential to generate profits. A high ROE indicates that the company is able to generate a significant return on the invested capital, making it an attractive investment. Coloplast is known for its products and services in the areas of urology, continence care, ostomy care, and wound and skin care, which have helped to ensure the company’s continued success.
– Cardiovascular Systems Inc ($NASDAQ:CSII)
Cardiovascular Systems Inc is a medical device company that develops, manufactures, and markets innovative interventional treatment systems for peripheral and coronary artery disease. The company has a market cap of 576.3M as of 2022 and a Return on Equity of -9.45%. This indicates that the company is not generating enough profits to cover its costs, which is not a good sign for the investors. Despite this, the company continues to innovate and develop new products in order to improve its financial performance.
Summary
ICU Medical is a medical device company that specializes in the development, manufacture, and distribution of infusion products, infusion therapy management systems, and infection prevention products. Recently, investment firm CL King Initiates has initiated coverage on the company’s stock. Analysts believe that the company’s strong product portfolio and presence in the fast-growing home health care market will help it maintain a competitive edge. Furthermore, its established relationships with several large distributors and solid reimbursement coverage are expected to drive further growth. With a wide variety of infusion products from IV pumps to catheters that are backed by reliable customer service, ICU Medical is well-positioned to capitalize on its potential.
Additionally, its tight control on costs is expected to result in higher profit margins going forward.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
